RxDoctor Payments Data

Tami Lewis, APRN

Family · Cape Coral, FLNPI 1528787801

Payments from drug & device makers

$1,241in general payments, 2019–2025

Across 47 payments — averaging $26.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$322
  • Johnson & Johnson$322
  • Takeda Pharmaceuticals U.S.A., Inc.$249
  • Biocon Biologics Inc$74
  • Exact Sciences$69
  • Sanofi$54
  • plus $150 from 6 others

What the payments were for

  • Food & beverage$1,14292%
  • Education$998%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,241 in reported general payments places this provider in the 70th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$7,463
Medicare patients
91
Services billed
96

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase48$81,832
LinzessLinaclotide20$17,420
SutabSod Sulf/Pot Chloride/Mag Sulf56$9,113
Sucralfate55$3,709
Lubiprostone23$2,383
Pantoprazole Sodium191$1,725
Omeprazole97$1,513
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates25$1,454
Ondansetron OdtOndansetron11$872
Dicyclomine Hcl51$648
Famotidine41$486
Lactulose65$467
Colestipol Hcl12$433
Esomeprazole Magnesium11$412
Ondansetron Hcl14$248

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$322$99,25268 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 14,618 family providers in Florida.

Other family in Cape Coral

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →